These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 15174009)
1. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Lang AE; Obeso JA Ann Neurol; 2004 Jun; 55(6):761-5. PubMed ID: 15174009 [No Abstract] [Full Text] [Related]
2. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Elsworth JD; Roth RH Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143 [TBL] [Abstract][Full Text] [Related]
3. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Hornykiewicz O Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366 [TBL] [Abstract][Full Text] [Related]
4. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease. Ogura T; Ogata M; Akita H; Jitsuki S; Akiba L; Noda K; Hoka S; Saji M Neurosci Res; 2005 Mar; 51(3):299-308. PubMed ID: 15710494 [TBL] [Abstract][Full Text] [Related]
5. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Marek K; Jennings D; Seibyl J Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107 [No Abstract] [Full Text] [Related]
6. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Hodaie M; Neimat JS; Lozano AM Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250 [TBL] [Abstract][Full Text] [Related]
7. "Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology. Greenamyre JT Funct Neurol; 2000; 15(2):67-80. PubMed ID: 10916718 [No Abstract] [Full Text] [Related]
8. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539 [TBL] [Abstract][Full Text] [Related]
9. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease. Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644 [TBL] [Abstract][Full Text] [Related]
10. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats]. Wang S; Qi XJ; Han D Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498 [TBL] [Abstract][Full Text] [Related]
11. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease. Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019 [TBL] [Abstract][Full Text] [Related]
12. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311 [TBL] [Abstract][Full Text] [Related]
13. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method. Orzi F; Fornai F; Blandini F Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530 [No Abstract] [Full Text] [Related]
14. Parkinson's disease: nigral receptor changes support peptidergic role in nigrostriatal modulation. Uhl GR; Hackney GO; Torchia M; Stranov V; Tourtellotte WW; Whitehouse PJ; Tran V; Strittmatter S Ann Neurol; 1986 Aug; 20(2):194-203. PubMed ID: 3019228 [TBL] [Abstract][Full Text] [Related]
15. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. Sajadi A; Bauer M; Thöny B; Aebischer P J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064 [TBL] [Abstract][Full Text] [Related]
16. Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease? Do Thi NA; Saillour P; Ferrero L; Paunio T; Mallet J Gene Ther; 2007 Mar; 14(5):441-50. PubMed ID: 17093508 [TBL] [Abstract][Full Text] [Related]
17. Prospects for gene therapy in Parkinson's disease. Freese A; Stern M; Kaplitt MG; O'Connor WM; Abbey MV; O'Connor MJ; During MJ Mov Disord; 1996 Sep; 11(5):469-88. PubMed ID: 8866488 [TBL] [Abstract][Full Text] [Related]
19. [ Is Parkinson's disease due to deficiency of dopamine?]. Castrén E Duodecim; 2005; 121(7):782-3; author reply 783-4. PubMed ID: 15909967 [No Abstract] [Full Text] [Related]
20. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat. González-Hernández T; Barroso-Chinea P; Rodríguez M Mov Disord; 2004 Sep; 19(9):1029-1042. PubMed ID: 15372592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]